[go: up one dir, main page]

MX2018008061A - Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. - Google Patents

Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.

Info

Publication number
MX2018008061A
MX2018008061A MX2018008061A MX2018008061A MX2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A
Authority
MX
Mexico
Prior art keywords
moiety
cnp
large carrier
carrier moieties
prodrug
Prior art date
Application number
MX2018008061A
Other languages
English (en)
Inventor
Rau Harald
Hersel Ulrich
Cleemann Felix
Elisabeth Rasmussen Caroline
Original Assignee
Ascendis Pharma Growth Disorders As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Growth Disorders As filed Critical Ascendis Pharma Growth Disorders As
Publication of MX2018008061A publication Critical patent/MX2018008061A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un profármaco del CNP o una sal del mismo farmacéuticamente aceptable que comprende una porción del CNP -D; y una porción portadora -Z que está conjugada a través de una porción -L2- a una porción enlazadora de profármaco reversible -L1-, en la cual la porción enlazadora de profármaco reversible -L1- está covalentemente e irreversiblemente conjugada a -D; en donde -L2- es un enlace químico o un espaciador; y -Z es un polímero que tiene un peso molecular de al menos 10 kDa. Además se refiere a composiciones farmacéuticas que comprenden el profármaco del CNP o una sal del mismo farmacéuticamente aceptable, su uso como un medicamento y a métodos de tratamiento.
MX2018008061A 2016-01-08 2017-01-05 Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. MX2018008061A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16150624 2016-01-08
EP16179286 2016-07-13
EP16191458 2016-09-29
PCT/EP2017/050201 WO2017118693A1 (en) 2016-01-08 2017-01-05 Cnp prodrugs with large carrier moieties

Publications (1)

Publication Number Publication Date
MX2018008061A true MX2018008061A (es) 2018-08-23

Family

ID=57838356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008061A MX2018008061A (es) 2016-01-08 2017-01-05 Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.

Country Status (8)

Country Link
US (6) US10835578B2 (es)
EP (1) EP3400020A1 (es)
JP (4) JP7051686B2 (es)
AU (2) AU2017205268B2 (es)
CA (1) CA3007976C (es)
MX (1) MX2018008061A (es)
WO (1) WO2017118693A1 (es)
ZA (1) ZA201804414B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
CN115177720A (zh) 2016-01-08 2022-10-14 阿森迪斯药物生长障碍股份有限公司 具有低npr-c结合的控制释放cnp激动剂
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
EP4223309A1 (en) 2016-09-29 2023-08-09 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
BR112019017103A2 (pt) 2017-03-10 2020-04-14 Quiapeg Pharmaceuticals Ab conjugados liberáveis
EP3773680A1 (en) * 2018-03-28 2021-02-17 Ascendis Pharma Oncology Division A/S Il-2 conjugates
US11357828B2 (en) 2018-09-12 2022-06-14 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
CN113423384B (zh) * 2019-02-11 2024-01-05 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂
TW202210502A (zh) 2020-06-03 2022-03-16 丹麥商阿森迪斯腫瘤製藥有限公司 新穎il-2序列及其用途
EP4164672A4 (en) * 2020-06-12 2024-10-09 PharmaIN Corporation C-TYPE NATRIURETIC PEPTIDES AND RELATED METHODS IN THE TREATMENT OF CANCER
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
IL316466A (en) 2022-05-23 2024-12-01 Ascendis Pharma Growth Disorders As Liquid pharmaceutical formulations of cnp compounds
US12077561B2 (en) 2022-11-02 2024-09-03 Novo Nordisk A/S CNP compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
KR100691545B1 (ko) 1998-09-28 2007-03-09 산텐 세이야꾸 가부시키가이샤 나트륨 이뇨 펩티드를 유효 성분으로하는 누액 분비 촉진또는 각결막 장해 치료용 점안제
DK2279755T3 (da) 2001-10-10 2014-05-26 Ratiopharm Gmbh Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
US8596542B2 (en) * 2002-06-04 2013-12-03 Hand Held Products, Inc. Apparatus operative for capture of image data
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
CA2824093C (en) 2004-03-23 2016-10-25 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8283318B2 (en) 2006-09-08 2012-10-09 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
ZA200902587B (en) 2006-11-09 2010-06-30 Alcon Res Ltd Water insoluble polymer matrix for drug delivery
US7950453B2 (en) * 2007-04-20 2011-05-31 Shell Oil Company Downhole burner systems and methods for heating subsurface formations
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
AU2008266448B2 (en) 2007-06-21 2013-06-13 Technische Universitat Munchen Biological active proteins having increased in vivo and/or vitro stability
EP2175878A4 (en) 2007-07-11 2014-12-03 Belrose Pharma Inc POLYMER DRUG DISPENSING SYSTEM WITH A MULTIPLE SUBSTITUTED AROMATIC PART
AU2008326327A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
RS58948B1 (sr) * 2008-02-01 2019-08-30 Ascendis Pharma As Prolek koji sadrži linker koji se može sam odcepiti
US20110105413A1 (en) 2008-05-23 2011-05-05 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
EP2334334A1 (en) 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of nesiritide peptides
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
BR122019026832B1 (pt) 2009-05-20 2021-08-24 Biomarin Pharmaceutical Inc Variantes de peptídeo natriurético tipo c (cnp), seu método de produção recombinante e seu uso, composição farmacêutica, composição para tratamento de uma condição ou distúrbio responsivo a cnp e célula hospedeira para produção in vitro de um peptídeo cnp
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
DK2566335T3 (en) 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
JP5964815B2 (ja) 2010-05-05 2016-08-03 プロリンクス リミテッド ライアビリティ カンパニー 固体担体からの放出制御薬物
BR112012029577B1 (pt) 2010-05-21 2022-04-12 Xl-Protein Gmbh Conjugado de fármaco compreendendo polipeptídeos helicoidais randômicos prolina/alanina biossintéticos, e composição farmacêutica ou diagnóstica
EP2741781A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
EP2741782B1 (en) 2011-08-12 2020-05-06 Ascendis Pharma A/S Protein carrier-linked prodrugs
EP2741779A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
WO2013024048A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
US20140249093A1 (en) 2011-08-12 2014-09-04 Ascendis Pharma A/S Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
CA2868925C (en) 2012-04-25 2020-01-21 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
EP2853273A4 (en) 2012-04-25 2016-01-13 Daiichi Sankyo Co Ltd PROMOTER FOR BONE REPAIR
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JPWO2015129812A1 (ja) 2014-02-27 2017-03-30 第一三共株式会社 ステロイド剤投与で誘発される成長障害に対する医薬
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
RU2728656C2 (ru) * 2015-01-09 2020-07-31 Асцендис Фарма Гроус Дизордерс А/С Cnp пролекарства
HUE057083T2 (hu) 2015-12-08 2022-04-28 Biomarin Pharm Inc C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
CN115177720A (zh) 2016-01-08 2022-10-14 阿森迪斯药物生长障碍股份有限公司 具有低npr-c结合的控制释放cnp激动剂
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
EP4223309A1 (en) * 2016-09-29 2023-08-09 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
CN113423384B (zh) 2019-02-11 2024-01-05 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂

Also Published As

Publication number Publication date
CA3007976C (en) 2023-09-26
AU2017205268A1 (en) 2018-06-07
US20190015481A1 (en) 2019-01-17
JP7692454B2 (ja) 2025-06-13
JP6951597B2 (ja) 2021-10-20
ZA201804414B (en) 2019-04-24
US20220296682A1 (en) 2022-09-22
AU2017205268B2 (en) 2022-02-17
CA3007976A1 (en) 2017-07-13
US20240316153A1 (en) 2024-09-26
JP7051686B2 (ja) 2022-04-11
JP2022088545A (ja) 2022-06-14
JP2019507724A (ja) 2019-03-22
JP7350123B2 (ja) 2023-09-25
EP3400020A1 (en) 2018-11-14
WO2017118693A1 (en) 2017-07-13
US11154593B2 (en) 2021-10-26
US20250127859A1 (en) 2025-04-24
AU2022201416A1 (en) 2022-03-24
JP2021100937A (ja) 2021-07-08
US10835578B2 (en) 2020-11-17
US20210077584A1 (en) 2021-03-18
JP2023175776A (ja) 2023-12-12
AU2022201416B2 (en) 2023-06-01
US20210177942A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
MX2018008061A (es) Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
MX2023013592A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
MX2024008222A (es) Hidrogeles de acido hialuronico degradables.
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015095811A3 (en) Combination therapy with neoantigen vaccine
NZ710729A (en) Amatoxin derivatives
HK1219422A1 (zh) 包含细胞结合剂及细胞毒素剂的轭合物
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2023002599A (es) Conjugados de compuestos de tubulisina cuaternizada.
MX2016010322A (es) Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
TN2018000393A1 (en) Pegylated carfilzomib compounds
IN2014DN08299A (es)
MY202884A (en) Compounds useful in hiv therapy
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
HK1219423A1 (zh) 包含细胞结合剂及细胞毒素剂的轭合物
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2021003186A (es) Nuevos conjugados de hidrogel.
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
WO2013157889A9 (ko) 신규한 아미노피리딘 유도체의 암 예방 또는 치료 용도